Inotiv Inc. experienced a dramatic surge in its stock price on Friday, with shares more than doubling to $0.2113 on volume exceeding 828 million shares. The jump came two days after the company filed for Chapter 11 bankruptcy protection, a move that includes a prepackaged restructuring plan that would wipe out all existing common equity with no payout to current holders.
The West Lafayette, Indiana-based contract research organization (CRO) entered bankruptcy with approximately $488.7 million in funded debt, according to a disclosure statement. The prepackaged plan, which was negotiated with key creditors before the filing, aims to eliminate roughly $326 million of debt through a debt-for-equity swap. Under the plan, creditors would take ownership of the company, and Inotiv would emerge as a private entity, likely within 50 days if the court approves.
Inotiv has secured $65.4 million in debtor-in-possession (DIP) financing, comprising $25 million in new funds and a $40.4 million roll-up from earlier bridge loans. The company also expects to obtain an exit term-loan facility of up to $150 million after exiting Chapter 11. President and CEO Bob Leasure stated that discussions with financial stakeholders have provided a "path forward" and that the restructuring will give Inotiv "additional flexibility" to execute its strategy.
Despite the stock's surge, the company issued a stark warning: trading its securities during the Chapter 11 process is "highly speculative," and the restructuring plan calls for canceling all existing common shares with no payout. The company also cautioned that there is no guarantee the restructuring will close. This leaves current investors at risk of losing their entire investment.
The bankruptcy filing comes amid significant financial pressure on Inotiv. The company reported approximately $27.5 million in interest expense for the first half of 2026 alone. Additionally, Inotiv faces competitive headwinds in the CRO and research-model markets, where it competes with larger public players and in-house pharmaceutical labs that possess greater capital and technical resources.
Inotiv also faces a potential delisting from Nasdaq. The company disclosed in January that it received a notice of noncompliance with the $1 minimum bid price rule, as its shares had not closed above $1 for 30 consecutive business days. The initial deadline to regain compliance is June 29, adding another layer of uncertainty for shareholders.
The broader market showed mixed reactions on Friday. Among larger life sciences services stocks, Charles River Laboratories fell about 1.3%, IQVIA declined 1.6%, and Labcorp edged up 1.3%. The iShares Russell 2000 ETF dropped 2.6%, and the SPDR S&P Biotech ETF slipped 2.2%.
Inotiv's next milestones are tied to the bankruptcy court process, not the usual earnings cycle. The restructuring plan includes a timeline of three days to secure interim financing approval, 45 days for final financing and court confirmation, and the plan expected to take effect in 50 days. The company's future now hinges on court approvals and the successful execution of its restructuring strategy.
